Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

HIV treatment news

Show

From To
Dolutegravir in HIV-1 infection: Added benefit in adult patients

The German Institute for Quality and Efficiency in Health Care (IQWiG) has determined that the new integrase inhibitor drug dolutegravir (Tivicay ®) is of considerable added benefit to treatment-naive patients in comparison with current first-line therapies, and some added benefit to patients who already need to take an integrase inhibitor.

Published
19 June 2014
From
Science Daily
The Man Who Was Immune to AIDS - But Not What Came After

A profile of Steve Crohn, who committed suicide in 2013. Crohn was discovered to be immune to HIV infection due to the CCR5 delta 32 polymorphism. The profile examines questions how survivor guilt and ageing in the New York gay community may have contributed to his suicide.

Published
18 June 2014
From
New York magazine
New global clinical trial aims to replicate the mysterious “Mississippi baby” success

Researchers plan to identify 54 HIV-positive infants and treat them with standard antiretroviral drugs, beginning treatment within 48 hours of birth. The team plans to enroll HIV-positive infants across 17 hospitals and clinics in the U.S. and 11 other countries, including Haiti, India, Malawi, South Africa and Thailand.

Published
18 June 2014
From
Scientific American
South Africa: Antiretrovirals Credited for TB Decline

South Africa is seeing about 79,000 fewer TB cases annually thanks to increased HIV treatment uptake, according to the latest research from the National Institute for Communicable Diseases (NCID)

Published
13 June 2014
From
Health-e
Glaxo's ViiV Joins J&J's Janssen to Develop Single-Pill HIV Drug

Glaxo’s majority-owned ViiV Healthcare venture is collaborating with Johnson & Johnson’s Janssen unit to test a pill combining ViiV’s Tivicay with Janssen’s Edurant, ViiV said today in a statement. Trials are expected to begin next year, the Brentford, U.K.-based company said.

Published
13 June 2014
From
Bloomberg
PrEP users say it provides an 'extra layer of protection' and 'peace of mind'

American gay men who have chosen to take pre-exposure prophylaxis (PrEP) are aware of their own risk of being exposed to HIV and see PrEP as providing

Published
12 June 2014
By
Roger Pebody
Paper explores new theory on spread of HIV by "popular" cells

"Popular" cells - could there really be such a thing? According to a new opinion paper published in PLoS Pathogens, the human body may contain cells that have more contact with other cells and could be "superspreaders" of the HIV virus.

Published
11 June 2014
From
HIV / AIDS News From Medical News Today
Researchers trace HIV adaptation to its human host

In a new study that traces the evolution of HIV in North America, researchers have found evidence that the virus is slowly adapting over time to its human hosts. However, this change is so gradual that it is unlikely to have an impact on vaccine design.

Published
11 June 2014
From
Science Daily
Novel approach found to reactivate latent HIV

A team of scientists at the Gladstone Institutes has identified a new way to make latent HIV reveal itself, which could help overcome one of the biggest obstacles to finding a cure for HIV infection.

Published
10 June 2014
From
HIV / AIDS News From Medical News Today
People starting therapy on a boosted protease inhibitor don't need to switch after one virological failure episode, study indicates

Remaining on the same regimen is a “reasonable” strategy for people taking first-line antiretroviral therapy (ART) based on a ritonavir-boosted protease inhibitor who experience virologic failure, according to

Published
09 June 2014
By
Michael Carter

Filter by country